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ABSTRACT (max 150 words) 
 
Cardiovascular disease (CVD) is higher in people with mental illness and is associated with a 
30 year higher mortality rate in this population. Erythrocyte docosahexaenoic acid (DHA) 
plus eicosapentaenoic acid (EPA) (omega-3 index) ≤ 4% is a marker for increased mortality 
risk from CVD while >8% is protective. Omega-3 polyunsaturated fatty acids are also 
important for brain function and may ameliorate symptoms of mental illness. We investigated 
the erythrocyte omega-3 index in people with mental illness. One hundred and thirty adults 
aged 18-65 years (32.6% male) with schizophrenia (n=14) and depression (n=116) provided 
blood samples and completed physiological assessments and questionnaires. Both 
populations had risk factors for metabolic syndrome and CVD. The average omega-3 index 
was 3.95% (SD=1.06), compared to an estimated 5% in the Australian population. These data 
indicate an unfavourable omega-3 profile in people with mental illness that could contribute 
to higher CVD risk.  
 
 
 
 
Keywords: polyunsaturated fatty acids, omega-3, omega-3 index, mental illness, depression, 
schizophrenia, cardiovascular disease 
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INTRODUCTION 
 In 2001 the World Health Organisation reported that around 450 million people worldwide 
suffered from a mental health problem and that one in four people will experience mental 
illness at some stage in their life [1]. Recent findings from the World Health Organisation’s 
World Mental Health survey identified that mental disorders are common across 28 
participating countries, with an interquartile range from 18.1-36.1 per cent of lifetime 
prevalence [2]. Like physical health, mental health is a complex interaction of biological, 
psychological and social factors [1]. Not only does chronic mental illness lead to substantially 
reduced quality of life, social and economic burden, it is compounded by high rates of 
physical illness. People with serious mental illness (SMI) are more likely to suffer from a 
range of physical health problems, particularly metabolic syndrome/diabetes and 
cardiovascular disease (CVD) [3-6]. Behavioural factors that lead to poor lifestyle choices 
such as smoking, diet and low physical activity contribute to this higher risk [1, 7]. Although 
medications also contribute to CVD risk factors, lifestyle factors such as poor diet (e.g. low 
fibre, high fat, high sugar) have been identified as independent contributors [8-10].  
 
These lifestyle behaviours may contribute to common underlying biological mechanisms for 
both physical and mental illness and their comorbidities [11]. Supporting evidence comes 
from a meta-analysis of epidemiological studies showing a significant association between 
depression and metabolic syndrome [6], a cluster of risk factors for CVD including 
hyperglycemia and/or insulin resistance, hypertension, abdominal adiposity and 
hyperlipidemia. Interestingly, prospective studies identified in the latter review showed that 
the association is bidirectional. Another meta-analysis showed that depressed adults have a 
37% increased risk of developing diabetes [5]. These studies provide evidence that people 
don’t develop depression as a result of being physical ill, and that in fact there may be 
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underlying mechanisms that manifest as mental illness before symptoms of physical illness 
become apparent.  
 
One of the possible common contributors to both cardiometabolic and mental health is the 
group of omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs). The benefits of n-3 
LCPUFA for cardiovascular health have been well established [12] (despite recent studies 
which are plagued by methodological issues, largely associated with the fact that they were 
conducted after 2000 and 2002 American Heart Foundation recommendations for increased 
fish and fish oil intake respectively, and subsequent exponential increase in fish oil imports 
[13, 14]). Mechanisms for reducing CVD risk may include reduction of ventricular 
arrhythmia, thrombosis, triglycerides, atherosclerotic plaque, inflammation and hypertension, 
and endothelial relaxation [15]. Based on the body of evidence, an omega-3 index for 
cardiovascular health was developed by Harris and von Schacky [16]. They first established 
erythrocyte levels of the long chain n-3 LCPUFAs eicosapentaenoic acid (EPA; 20:5n-3) plus 
docosahexaenoic acid (DHA; 22:6n-3) as a valid biomarker of omega-3 status. Then by 
pooling together results from a body of large prospective and randomised controlled trials 
they identified that a combination of EPA plus DHA levels of ≤ 4% in erythrocyte 
membranes was associated with the highest risk of mortality from coronary heart disease 
(CHD) whereas levels ≥ 8% conferred the greatest cardioprotection. Therefore the omega-3 
index was proposed as a useful biomarker to estimate risk of mortality from CHD and 
provide targets for reducing mortality risk. 
 
Since the prevalence of n-3 LCPUFA DHA in brain tissue was discovered in the 1970s [17] a 
number of pivotal roles have been identified for DHA in brain function, including a key 
structural role in brain cells and phospholipids, neurite growth, membrane fluidity, 
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neurotransmission (e.g. synthesis of neurotransmitters serotonin and dopamine), endothelial 
function and brain barrier integrity, neuronal survival and protection from neurodegeneration 
[18]. The role of EPA and DHA in improving endothelial function via production of anti-
inflammatory eicosanoids, reducing adhesion of substances to the endothelial wall and 
influence on nitric oxide production (and therefore vasodilation and blood flow) may 
contribute to common underlying mechanisms for their protective role in cardiovascular and 
mental health [19]. A growing body of work has investigated the role of n-3 LCPUFAs in 
mental health with indications of benefit across the lifespan including developmental 
disorders, depression, schizophrenia and cognitive decline [20, 21]. Following the latter 
studies reviewed, a robust multi-centre trial reported that n-3 LCPUFA supplementation for 
12 weeks was able to significantly reduce transition to psychosis at 12 month follow-up 
compared to placebo in young people at high risk for psychosis [22]. We previously proposed 
an omega-3 index for mental health although there were as yet insufficient blood fatty acid 
data to establish this [23]. 
 
Inflammation has been proposed as a possible mediating role for comorbid physical and 
mental illness [24-28] and may be one of the mechanisms by which n-3 PUFA exert their 
effects. The anti-inflammatory properties of eicosanoids produced by EPA counteract the 
largely inflammatory properties of eicosanoids produced by arachidonic acid (AA) from the 
n-6 PUFA series. The n-3 and n-6 PUFA series compete for the same enzymes for elongation 
and desaturation, and a higher intake of one can displace the other in cell membranes. This is 
of concern in Western societies that have increased the intake of n-6 PUFA via vegetable oils 
and processed foods while decreasing intake of n-3 PUFA from nuts, seeds, dark leafy 
vegetables and fatty fish, including Australia [29, 30]. It has been proposed therefore that the 
ratio of n-6/n-3 PUFAs, which in Western diets is estimated at 15-16/1 (8/1 in Australia [30]) 
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compared to an equal ratio in traditional diets, contributes to pro-inflammatory states that 
underlie chronic illness [31]. 
 
In the present study we investigated erythrocyte PUFA levels in people with SMI to 
determine their erythrocyte omega-3 index and associations with physical and mental health. 
This study utilised baseline data from two related studies: a pilot study with residents of a 
Community Rehabilitation Centre for people with serious mental illness and a randomised 
controlled trial with community dwelling people suffering from depression.  
 
METHOD 
Study 1 was a partnership between the University of South Australia and the Mental Health 
Directorate in the Southern Adelaide Local Health Network. Ethics approval was obtained 
from the Southern Adelaide Clinical Human Research Ethics Committee (HREC) and the 
HREC at the University of South Australia. For study 2 community dwelling adults suffering 
depressive symptoms were recruited, for which ethics approval was provided by the HREC at 
the University of South Australia. Both studies aimed to investigate the effect of a 
Mediterranean-style diet and fish oil supplementation on cardiometabolic and mental health 
(HELFIMED: Healthy Eating for Life with a Mediterranean-style Diet), the first as a pilot 
feasibility study [32] and the second as a randomised controlled trial [33]. This report utilises 
baseline data from those studies. For study 1 information sessions were conducted to explain 
the project to staff and residents of a Community Rehabilitation Centre (CRC) with 20 beds 
for people with serious mental illness. The population is transient with an average stay of 
around 9 months. Ongoing recruitment was undertaken for the pilot feasibility study from 
May 2013 to February 2014 and was open to all new residents entering the CRC during that 
time. All consenting residents were eligible to take part. For study 2 we recruited community 
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dwelling people via newspaper advertisements, media releases, social media and a 
recruitment agency. Inclusion criteria were depressive symptoms over the past 3 months or 
more, age between 18-65, poor diet according to an adapted dietary screening tool and not 
consuming fish oil supplements over the past 3 months. 
 
Participants 
Over an 8-month period, 25 CRC residents aged 18-59 years with schizophrenia signed up 
for study 1 and completed baseline assessments. In the first batch of blood samples many 
were oxidised due to an inappropriate protocol for washing of the red blood cells which was 
then rectified. Therefore, 14 blood samples were available for analysis of erythrocyte fatty 
acids. In study 2, 164 participants aged 18-65 completed baseline assessments. Of those, 116 
people had either diagnosed depression (n=75; 58%) and/or depressive symptoms in the 
‘severe’ or ‘extremely severe’ range on the Depression, Anxiety, Stress scale (DASS-21) [34] 
and are included in these analyses. Summary characteristics are provided in Table 1.  
 
Assessments 
Baseline assessments included fasted blood samples, weight, height, waist circumference and 
blood pressure, and the following questionnaires: the Assessment of Quality of Life (AQoL)-
8D scale [35] in both studies and the DASS-21 [34] and Positive and Negative Affect Scale 
(PANAS) in study 2. These are described below. A background questionnaire measured the 
following potential covariates: age, gender, socio-economic status (Socio-Economic Indexes 
for Areas decile), education level (1=completed primary school; 8=postgraduate degree), 
household income, physical activity (calculated as total minutes per week), smoking status 
(1=never smoked; 5=smoke daily), and frequency of consuming >2 alcoholic drinks per day 
(1=never/rarely; 5=daily). 
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Fatty acids 
Fasted blood samples were collected by trained phlebotomists in 6ml EDTA tubes. Red blood 
cells were separated from plasma by low speed centrifugation and packed red blood cells 
were stored in 1ml micro tubes at -80C until analysis. Erythrocyte samples were thawed and 
prepared for fatty acid analysis according to Swierk et al [36] using the direct 
transesterification procedure according to Lepage and Roy [37]. Samples were analysed by 
flame-ionisation gas chromatography (model GC-17A, Shimadzu) using a 50m x 0.25mm 
internal diameter capillary column. One microlitre of the sample was auto-injected into the 
column, and individual fatty acids were quantified using the Shimadzu analysis software 
(Class-VP 7.2.1 SP1, USA). Fatty acid peaks were identified by comparison with known fatty 
acid standards and quantitated by comparison to the 21:0 internal standard (Nu-chek and 
Sigma). Erythrocyte EPA plus DHA as a percent of cell membranes was calculated to obtain 
the omega-3 index as reported by Harris and von Schacky [16]. 
 
AQoL-8d 
The AQoL-8d is a 35-item questionnaire that is used to measure quality of life. The 35 items 
load onto eight dimensions, of which three represent physical domains of quality of life 
(independent living, pain and senses) and five represent psychological domains (happiness, 
self-worth, coping, relationships, mental health). These load onto two super dimensions 
(physical and psycho-social). The scores from each dimension are combined to create a final 
AQoL-8D utilities score for use in economic evaluation studies. The AQoL-8D has good 
validity and internal consistency with alpha coefficients of 0.89-0.96 [38].  
 
DASS-21 
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The DASS is a 21-item self-report scale which provides a measure of the level of negative 
emotional states of depression, anxiety and stress. It is a highly reliable measure that shows 
high convergent validity and has good internal consistency with a Cronbach alpha of 0.82-
0.93 [34, 39] Ronk et al. 2013). DASS-21 sub-scale severity ratings are calculated based on 
the full DASS-42 severity rating [40]. The scale was multiplied by two and divided into the 
severity categories to yield equivalent scores ranging from 1-5. Those with severity ratings of 
4 and 5 (severe and extremely severe; study 2) are included in this study. 
 
PANAS 
The PANAS is a 20-item scale measuring positive and negative emotions. It has been 
validated and demonstrates reliable psychometric properties, discriminant, convergent and 
constructed validity. The reliability (internal consistency) of the PANAS positive and 
negative emotions scales were determined to be α =.89 and .85 respectively [41].  
 
Statistical analysis 
Descriptive statistics were used to identify the omega-3 index, demographic, cardiovascular 
and mental health parameters. Pearson correlations were used to investigate bivariate 
associations between the omega-3 index, mental and cardiometabolic health outcome 
measures. For any significant associations between the omega-3 index and physical or mental 
health, potential covariates that were significantly associated with outcome variables were 
planned to be entered into regression analyses to control for these. Significance for 
correlations was set at P < 0.01 to allow for multiple comparisons. 
 
RESULTS 
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As can be seen in Table 1, average data for each sample show that both samples had CVD 
risk factors with BMI in the obese range, central adiposity, elevated blood pressure for 
participants in study 2 and slightly elevated fasting glucose in the study 1 sample. The 
average omega-3 index for the whole sample was 3.95% (SD = 1.06) of erythrocyte 
membranes. The majority (56%) of participants had an omega-3 index in the high risk range 
≤ 4%, and the remaining 44% in the medium risk range from 4-8% (with only 6 participants 
or 4.6% with an omega-3 index > 6%). No participants had an omega-3 index ≥ 8%, the 
range that confers highest protection against mortality from CVD. Participant data are broken 
down by group in Table 1 and the distribution of the omega-3 index is shown in Figure 1. 
 
 
 
 
Figure 1: Distribution of the omega-3 index  
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Table 1: Summary characteristics, omega-3 index, omega-6 and omega-3 polyunsaturated 
fatty acid levels of study participants (N=130) 
 Reference range CRC Mood Study 
  n M (SD) n M (SD) 
Age n/a 14 29.00 (11.29) 118 43.90 (13.07) 
Gender  n/a 14 71.4% male 118 28% male 
Fasting blood glucose 4-6 mmol/L 11 6.15 (0.95) - N/A 
Waist circumference (male) < 94 cm 9 107.78 (22.58) 31 102.67 (19.71)
Waist circumference (female) < 80 cm 3 91.33 (13.43) 81 93.72 (19.82) 
BMI (weight/height2) 18.5-25  
[> 30 = obese] 
10 30.97 (6.53) 112 30.77 (8.13) 
Diastolic blood pressure < 80 mmHg 9 74.83 (9.09) 111 80.06 (10.25) 
Systolic blood pressure < 120 mmHg 9 112.44 (11.58) 111 120.98 (15.42)
Omega-3 index  
(EPA + DHA) 
≤ 4% ↑ risk; ≥ 8%  
↓ risk for  CVD 
mortality 
14 4.04 (0.63) 116 3.92 (1.09) 
CRC = Community Rehabilitation Centre (participants with schizophrenia); Mood Study = 
community dwelling participants with diagnosed depression and/or severe/extremely severe 
depression scores on the 21-item Depression Anxiety Stress Scale (DASS-21). 
 
Pearson correlations between the omega-3 index, mental health and health-related quality of 
life are shown in Table 2. There were no significant associations between the omega-3 index 
and mental health, quality of life or cardiometabolic health outcomes. Therefore it was not 
possible to run regression analyses as planned.  
 
Table 2: Pearson correlations between erythrocyte fatty acids, mental health and health-
related quality of life, N=116-130† 
12 
 
 Omega-3 index 
Depression (DASS) -0.058 
Anxiety (DASS) -0.048 
Stress (DASS) -0.144 
Positive affect (PANAS) 0.084 
Negative affect (PANAS) -0.001 
AQoL Independent living 0.119 
AQoL Happiness 0.024 
AQoL Mental health 0.026 
AQoL Coping -0.004 
AQoL Relationships -0.011 
AQoL Self worth 0.140 
AQoL Pain -0.017 
AQoL Senses -0.080 
AQoL Super dimension psycho-social -0.013 
AQoL Super dimension physical  health 0.020 
Systolic blood pressure (mmHg) -0.068 
Diastolic blood pressure (mmHg) -0.045 
Body mass index (BMI; h/m2) -0.117 
Waist circumference -0.021 
Apolipoprotein B/A1 ratio 0.049 
*p < 0.05; **p < 0.01. †N varies due to missing data on individual subscales and/or some 
scales only completed by Mood Study cohort. DASS = Depression, Anxiety, Stress Scale 
(21-item); PANAS = Positive And Negative Affect Scale; AQoL = Assessment of Quality of 
Life 8-d scale 
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DISCUSSION 
In this study we analysed PUFA data from people with SMI, i.e. schizophrenia and severe 
depressive symptoms, and determined their overall omega-3 index to be less than 4% which 
is in the range that has been identified as high risk for mortality from CVD [16]. We know 
that n-3 PUFA intake in Western societies is low generally, and this could be a contributor to 
the high global mortality from CVD [42]. The average omega-3 index in the Australian 
population is 5% [36, 43]. In our population of people with mental illness, the omega-3 index 
is even lower, potentially placing them at greater risk for mortality from CVD. Consistent 
with this, our sample of people with mental illness had, on average, risk factors for metabolic 
syndrome and CVD including elevated blood glucose, BMI in the obese range and excessive 
abdominal adiposity. However these did not correlate with the omega-3 index. A review by 
von Schacky reported an omega-3 index of between 2.90-7.15% in a range of populations in 
western countries (with high incidence of CHD) and 3.47-12.83% in Asian countries (with 
low incidence of CHD). In all studies low omega-3 index was associated with a worse health 
condition. In addition to those cited in the review, a Korean study reported an omega-3 index 
of 8.83% in patients with acute STEMI compared to 11.13% in healthy controls, and the 
omega-3 index was inversely associated with the odds for being a STEMI patient [44]. A 
meta-analysis by Lin et al reported lower EPA and DHA in depressed patients than controls 
(actual levels not reported). McNamara et al. found a lower omega-3 index in American 
patients with major depressive disorder (3.8% ± 0.2) and bipolar disorder (3.3% ± 0.2) 
compared with healthy controls (4.8% ± 0.3) [45]. 
 
As outlined earlier, a number of mechanisms have been identified for the roles of n-3 
LCPUFA in the brain [18, 21] that include potentially vascular mechanisms which may 
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underlie both cardiovascular and mental health [19]. Further supportive of this, Canadian 
researchers investigated n-3 PUFA levels in people who had suffered an acute myocardial 
infarction and found that those who suffered major depression had notably lower n-3 PUFA 
levels and omega-3 index (4.46%) than those without depression (5.05%) [46]. Another very 
interesting study showed in a rat model that a high fructose drink increased triglycerides and 
insulin resistance in the brain, and that this effect was attenuated with an n-3 rich diet. 
Furthermore, increased insulin resistance and triglyceride levels were associated with poorer 
performance on a cognitive task. The authors suggested that this may provide evidence of 
metabolic syndrome in the brain, which is exacerbated by n-3 PUFA deficiency [47]. 
Therefore there may be utility in translation of the omega-3 index from cardiovascular to 
mental health. 
 
Similarly to McNamara et al. [45], and as with our cardiometabolic health outcomes, there 
were no associations between the omega-3 index and mental health or quality of life. This 
may be either because there is no association with the measures used in the sample or because 
these n-3 PUFA levels were too low across the population. This would need to be 
investigated further in a sample with greater variability in omega-3 levels, across the low and 
high risk range for mortality from CHD. 
 
The low levels of n-3 LCPUFAs EPA and DHA in this sample of people with mental illness 
and CVD risk factors is of concern. Given the role of these PUFAs in cardiovascular and 
mental health, this is an issue that requires further consideration in terms of developing a 
strong evidence base for translation into policy and practice. The direct roles of n-3 
LCPUFAs, particularly DHA, in brain function and growing evidence of their ability to 
reduce symptoms of mental illness suggest that an omega-3 index or its equivalence might 
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similarly provide a useful target for estimating risk of mental illness and targets for treatment. 
As well as being a good indicator of n-3 PUFA levels in cardiac tissue, erythrocyte levels 
correspond to those found in brain tissue [48]. More studies are needed to establish baseline 
erythrocyte n-3 and n-6 PUFA levels that are associated with highest risk of mental illness, 
and correlate increased levels following n-3 PUFA supplementation with improved mental 
health outcomes to determine levels that are associated with greatest protection. It would be 
useful for intervention studies to be conducted over at least 6 months to enable maximum 
saturation of cell membranes [49], recruit people with low omega-3 index with the aim of 
reaching the target range (> 8%) [42] and to identify critical periods that provide maximum 
opportunity for prevention, e.g. in teenage years for young people at high risk for psychosis, 
when n-3 PUFA supplementation appears to provide optimal protection against transition to 
psychosis [22]. 
 
In conclusion, the omega-3 index was very low in this population of people with SMI. This is 
of concern given the associations between such a low omega-3 index and increased risk of 
mortality from CVD.  
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